Clinical Trial Update: A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) Plus Ribavirin in Hemophiliac Patients With Chronic Hepatitis C. [Phase 4]

View source ↗

Summary

This Phase 4 study evaluated peginterferon alfa-2a (PEGASYS) plus ribavirin in hemophiliac patients with chronic hepatitis C; the trial status is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• Pegasys (pegylated interferon alfa-2a)
• Ribavirin (ribavirin)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Hepatitis C, Chronic | Phase 4 | Status: COMPLETED